Tirzepatide and Cancer: What Does the Evidence Say?

What did the clinical trials actually find regarding cancer?

The SURMOUNT-1 trial, which enrolled 2,539 adults with obesity over 72 weeks, was the largest weight-management study of tirzepatide published to date. Across that programme, cancer was not identified as an adverse event associated with tirzepatide use. The trial results, published in the New England Journal of Medicine, reported a side-effect profile led by gastrointestinal symptoms (nausea, diarrhoea, constipation) not oncological events. NICE reviewed the full evidence package when issuing its recommendation for tirzepatide in December 2024, and no cancer-related signal altered that recommendation. That said, clinical trials run for months to a few years, and some cancers develop over decades. If you want a thorough look at what the evidence says about whether Mounjaro causes cancer, including how regulators have interpreted the data, that is covered in detail elsewhere on this site. This is not a gap unique to tirzepatide; it is simply the nature of how medicines are studied before and after licensing.

If you are weighing up whether tirzepatide is right for your situation, the overview of tirzepatide covers the broader evidence base, including what the trials measured and how results are reported. The prescriber who reviews your consultation at nume will also consider your individual medical history before any decision is made.

What is the thyroid cancer concern, and does it apply to people?

The thyroid question comes up often, and it is worth unpacking carefully. In preclinical animal studies, GLP-1 receptor agonists (including the GLP-1 component of tirzepatide) were shown to cause thyroid C-cell tumours in rodents when given at doses far above clinical levels over long periods. This led regulators to include a warning in the prescribing information, and it is why a history of medullary thyroid carcinoma or MEN2 is a contraindication. Anyone with that personal or family history should not take tirzepatide.

The critical context is that rodent thyroid C-cells respond to GLP-1 receptor stimulation in a way that human thyroid C-cells appear not to. Human thyroid tissue has far fewer GLP-1 receptors than rodent tissue. Post-marketing surveillance across the broader class of GLP-1 medicines, which have been in clinical use since the mid-2000s, has not established a causal link to medullary thyroid cancer in people. Regulators including the MHRA continue to watch for any emerging signal. The detailed discussion of whether Mounjaro can cause cancer goes further into this distinction if you want more depth on the rodent-versus-human biology.

Are there any cancer types where tirzepatide might have a protective effect?

This is an active area of scientific interest rather than established fact, so the framing here matters. Obesity is a recognised risk factor for a number of cancers (including breast, colorectal, endometrial and oesophageal cancers) and sustained weight reduction is associated with lower risk across several of those types. If tirzepatide produces meaningful, sustained weight loss, the logic follows that it could reduce obesity-related cancer risk indirectly. Some researchers are also exploring whether GLP-1 receptor agonists have direct anti-tumour properties at the cellular level, but that work is preliminary and mostly preclinical.

None of this means tirzepatide is a cancer-prevention medicine. It is licensed for weight management and type 2 diabetes. The potential downstream benefits of weight reduction are real and worth discussing with a clinician, but they are separate from any direct oncological claim. The guidance on Mounjaro for people who have had cancer covers a related and important question: whether tirzepatide is suitable for someone with a cancer history, which is always a conversation between the individual and their prescribing team.

What should you do if cancer history is part of your picture?

If you have a personal history of cancer (whether currently in treatment, in remission, or years clear) this is something a prescriber needs to know before they can assess whether tirzepatide is appropriate. Oncology teams and prescribers often work together in these situations, and the answer is not automatically no; it depends on the cancer type, treatment history and current health status. What it is never is a decision made by filling in a form alone.

A question our prescribers hear regularly is whether past cancer disqualifies someone from weight-loss treatment. It does not, as a blanket rule, but it does require careful individual review. You can read more about the specific considerations around Mounjaro and breast cancer, which is one of the cancer types patients ask about most often. If cost is a consideration as you think through your options, the Mounjaro price comparison page sets out what private treatment realistically involves. And if you have a question that sits between what these pages cover, our team is reachable seven days a week.

The NHS tirzepatide guidance available at nhs.uk/medicines/tirzepatide includes a clear summary of who should not use this medicine and what to report to a prescriber — it is a useful first read alongside any clinical conversation. If you are ready to have that conversation, our prescribers review every consultation the same day.